共 360 条
[1]
Liu J(2021)Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017 Hum Reprod 36 1108-1119
[2]
Wu Q(2016)Poly cystic ovarian syndrome: an updated overview Front Physiol 5 124-9.e1–11
[3]
Hao Y(2023)Polycystic ovary syndrome: etiology, current management, and future therapeutics J Clin Med 12 1454-3946
[4]
Jiao M(2011)Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis Fertil Steril 95 1073-457
[5]
Wang X(2022)Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement Eur Heart J 43 3925-462
[6]
Jiang S(2022)Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies J Clin Med 11 6040-3875
[7]
Han L(1997)Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome Metabolism 46 454-263
[8]
El Hayek S(2001)Smaller LDL particle size in women with polycystic ovary syndrome compared to controls Clin Endocrinol (Oxf) 54 455-3340
[9]
Bitar L(2002)Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state J Clin Endocrinol Metab 87 3871-154
[10]
Hamdar LH(2005)Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome Gynecol Endocrinol 20 258-136